help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SELDON, P. M.
Right arrow Articles by GIEMBYCZ, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SELDON, P. M.
Right arrow Articles by GIEMBYCZ, M. A.

Am. J. Respir. Crit. Care Med., Volume 157, Number 3, March 1998, 803-809

Albuterol Does Not Antagonize the Inhibitory Effect of Dexamethasone on Monocyte Cytokine Release

PAUL M. SELDON, DAVID A. STEVENS, IAN M. ADCOCK, BRIAN J. O'CONNOR, PETER J. BARNES, and MARK A. GIEMBYCZ

Thoracic Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, London; and Department of Thoracic Medicine, King's College Hospital, London, United Kingdom

beta 2-Adrenoceptor agonists given by the inhaled route are the most effective bronchodilators known, yet high doses of these drugs may be associated with an increase in asthma mortality and morbidity. One theory for this paradox is that chronic use of beta 2-adrenoceptor agonists compromises the anti- inflammatory action of glucocorticosteroids. This hypothesis derives from the ability of albuterol and fenoterol to inhibit the interaction of the glucocorticosteroid receptor (GR) with proinflammatory transcriptional activators acting on the promoter region of certain target genes that encode cytokines such as tumor necrosis factor-alpha (TNFalpha ) and granulocyte/macrophage colony-stimulating factor (GM-CSF). However, the functional relevance of these results has not been formally investigated. We have tested the hypothesis that albuterol reduces the ability of dexamethasone to inhibit the generation of TNFalpha and GM-CSF from lipopolysaccharide (LPS)-stimulated human monocytes. Pretreatment of human monocytes with albuterol (1 and 100 µM) for 5 and for 180 min inhibited maximally TNFalpha generation by approximately 25%. However, regardless of the concentration of albuterol, or the time of preincubation, the inhibitory effect of dexamethasone was not significantly affected with respect to the EC50 or the maximal effect produced. Qualitatively identical data were obtained when GM-CSF release was used as an index of monocyte activation. We conclude that high concentrations of albuterol do not compromise the ability of dexamethasone to suppress the generation of TNFalpha and GM-CSF from LPS-stimulated human monocytes.




This article has been cited by other articles:


Home page
Eur J Heart FailHome page
R. Sharma, A. P. Bolger, M. Rauchhaus, S. von Haehling, W. Doehner, I. M. Adcock, P. J. Barnes, P. A. Poole-Wilson, H.-D. Volk, A. J.S. Coats, et al.
Cellular endotoxin desensitization in patients with severe chronic heart failure
Eur J Heart Fail, August 1, 2005; 7(5): 865 - 868.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. V. Culpitt, D. F. Rogers, P. Shah, C. De Matos, R. E. K. Russell, L. E. Donnelly, and P. J. Barnes
Impaired Inhibition by Dexamethasone of Cytokine Release by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., January 1, 2003; 167(1): 24 - 31.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
F M Spoelstra, D S Postma, H Hovenga, J A Noordhoek, and H F Kauffman
Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts
Thorax, March 1, 2002; 57(3): 237 - 241.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
P.J. Barnes
Scientific rationale for inhaled combination therapy with long-acting {beta}2-agonists and corticosteroids
Eur. Respir. J., January 1, 2002; 19(1): 182 - 191.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
G. Caramori, S. Lim, K. Ito, K. Tomita, T. Oates, E. Jazrawi, K.F. Chung, P.J. Barnes, and I.M. Adcock
Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies
Eur. Respir. J., September 1, 2001; 18(3): 466 - 473.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S.H. Korn, A. Jerre, and R. Brattsand
Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells
Eur. Respir. J., June 1, 2001; 17(6): 1070 - 1077.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
D R Taylor and R J Hancox
Interactions between corticosteroids and beta agonists
Thorax, July 1, 2000; 55(7): 595 - 602.
[Full Text]


Home page
Am. J. Respir. Crit. Care Med.Home page
G. P. ANDERSON
Interactions between Corticosteroids and beta -Adrenergic Agonists in Asthma Disease Induction, Progression, and Exacerbation
Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): S188 - 196.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society
  ATS Coding and Billing Quarterly